Update shared on15 Jul 2025
Fair value Decreased 35%A sharp decline in net profit margin alongside a surge in future P/E indicates worsening profitability and a more expensive valuation, justifying the substantial reduction in Tatva Chintan Pharma Chem's fair value price target from ₹1139 to ₹742.
WHAT'S IN THE NEWS
- Received an export order worth USD 3.56 million (INR 299.5 million) for Specialty Chemicals under the Pharma & Agro Intermediates & Speciality Chemicals category, to be delivered in Q3 FY26.
- Board recommended a final dividend of INR 1 per equity share (10% of face value), pending shareholder approval.
- Scheduled Board meeting to consider audited financial results for FY25 and to recommend a final dividend, subject to shareholder approval.
VALUATION CHANGES
Summary of Valuation Changes for Tatva Chintan Pharma Chem
- The Consensus Analyst Price Target has significantly fallen from ₹1139 to ₹742.00.
- The Future P/E for Tatva Chintan Pharma Chem has significantly risen from 28.11x to 63.43x.
- The Net Profit Margin for Tatva Chintan Pharma Chem has significantly fallen from 17.31% to 6.56%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.